But is Rybrevant deep enough, and does ficerafusp use the right pivotal dose?
ApexOnco Front Page
Recent articles
2026’s first big oncology buyout is here.
Data with the T-cell engager ASP2138 look lukewarm, but could improve with combos.
And Vironexis’s second gene therapy-encoded T-cell engager will soon go clinical.
The biggest Q3 agreement was AbbVie’s $700m swoop for Glenmark's trispecific T-cell engager.
The group toplines a phase 2 win with Alphamedix.
A phase 3 trial of Hernexeos in adjuvant HER2m NSCLC is planned.
And Treeline and HengRui also get in on the pan-RAS act.
